Brief: X4 Pharmaceuticals Announces $125 Million Capital Infusion From $105 Million Sale Of Priority Review Voucher And $20 Million Drawdown From Existing Loan Facility
09/05/2024 12:47
May 9 (Reuters) - Hercules Capital Inc HTGC.N :
* X4 PHARMACEUTICALS ANNOUNCES $125 MILLION CAPITAL INFUSION
FROM
$105 MILLION SALE OF PRIORITY REVIEW VOUCHER AND $20 MILLION
DRAWDOWN FROM EXISTING LOAN FACILITY
* X4: $125 MILLION OF NON-DILUTIVE CAPITAL EXTENDS PROJECTED
CASH
RUNWAY INTO LATE 2025, EXCLUDING EXPECTED COMMERCIAL SALES FROM
XOLREMDI
Source text for Eikon: ID:nGNX1Hk6PK
Further company coverage: HTGC.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule